Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All

Horizon Pharma Loses $11.6 Million in Second Quarter

August 31, 2011 12:07 pm | News | Comments

Horizon Pharma Inc. recorded an $11.6 million loss in the second quarter, its last quarter before the completion of an initial public offering of stock last month.

TOPICS:

Dr. Reddy's, Pfizer Settle Lipitor Patent Lawsuit

August 31, 2011 12:02 pm | News | Comments

Dr. Reddy's Laboratories Ltd. said on Aug. 31 that it settled a lawsuit brought by Pfizer Inc. over a generic version of Pfizer's cholesterol drug Lipitor.

Drug Study Receives OK from Monitoring Board

August 31, 2011 11:58 am | News | Comments

Keryx Biopharmaceuticals Inc. said on Aug. 31 that an independent monitoring board recommended that its late-stage study of a potential colorectal cancer treatment can continue as planned until it is completed.

Advertisement

Computer Model Developed for Testing Heart-Disease Drugs

August 31, 2011 11:54 am | News | Comments

University of California, Davis researchers developed a computer model to test the effects of medications for arrhythmia, or abnormal heart rhythm, before they are used in patients.

Protein Thermal Shift

August 31, 2011 8:22 am | Product Releases | Comments

Life Technologies is now offering Protein Thermal Shift complete solution, an application for Applied Biosystems real-time PCR systems that enables analysis of protein thermal stability.

TOPICS:

Two-Photon Microscopy

August 31, 2011 8:12 am | Product Releases | Comments

Special Optics offers objective lens solutions optimized for use in two-photon microscopy systems. These apochromatic objectives are customized with high numerical apertures and long working distances for use with various sample sizes and applications.

TOPICS:

3M Licenses BART Technology

August 31, 2011 8:04 am | News | Comments

Lumora Ltd and 3M have signed a joint development and licensing agreement. Conclusion The agreement allows 3M to develop and sell nucleic acid test kits utilising Lumora’s BART technology.

TOPICS:

New Device to Attack Heart of Tumors

August 31, 2011 7:55 am | News | Comments

Researchers have created and tested miniature devices that are implanted in tumors to generate oxygen, boosting the killing power of radiation and chemotherapy.

TOPICS:
Advertisement

COTI-2 Inhibits Cancer Cells

August 31, 2011 7:48 am | News | Comments

Critical Outcome Technologies Inc. announced recent experiments demonstrating clear evidence of COTI-2's ability to significantly inhibit the growth of cancer cells that over express Akt/Akt2, confirming it as a promising targeted therapy candidate.

TOPICS:

Daiichi Sankyo Submits sNDA

August 31, 2011 7:34 am | News | Comments

Daiichi Sankyo Company submitted a supplemental New Drug Application for an additional indication of Diagnogreen 25 mg intravenous injection for near-infrared fluorescence angiography during cerebrovascular surgery.

TOPICS:

Valeant Buying Afexa for $77M

August 31, 2011 7:26 am | News | Comments

Canadian drugmaker Valeant Pharmaceuticals International Inc. said it will buy cold remedy maker Afexa Life Sciences Inc. for about $77.6 million.

TOPICS:

Analyst Upgrades Alkermes' Shares

August 31, 2011 7:22 am | News | Comments

A Caris & Co. analyst upgraded the stock of drug developer Alkermes Inc., pointing to the company's pending acquisition of a drug technology business.

TOPICS:

Rough Start for Benlysta

August 31, 2011 7:14 am | News | Comments

A new lupus treatment developed by Human Genome Sciences Inc. is receiving a lukewarm reception from doctors so far, with demand for the drug shaping up to be much softer than expected, according to a Citi analyst.

TOPICS:

NIH Database to Speed Research Up for Brain Injuries

August 30, 2011 12:32 pm | News | Comments

The National Institutes of Health, in partnership with the Department of Defense, is building a central database on traumatic brain injuries.

TOPICS:

Kuros Completes Patient Recruitment for KUR-023

August 30, 2011 12:28 pm | News | Comments

Kuros Biosurgery completed patient recruitment in a clinical trial investigating the safety and efficacy of KUR-023, its novel dural sealant product candidate.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading